Publicação
Open-label placebo treatment in chronic low back pain: A randomized controlled trial
| datacite.subject.fos | Ciências Sociais::Psicologia | |
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| dc.contributor.author | Cláudia Carvalho | |
| dc.contributor.author | Joaquim Machado Caetano | |
| dc.contributor.author | Lidia Cunha | |
| dc.contributor.author | Paula Rebouta | |
| dc.contributor.author | Ted J. Kaptchuk | |
| dc.contributor.author | Irving Kirsch | |
| dc.date.accessioned | 2026-06-17T18:01:27Z | |
| dc.date.available | 2026-06-17T18:01:27Z | |
| dc.date.issued | 2016-12 | |
| dc.description.abstract | This randomized controlled trial was performed to investigate whether placebo effects in chronic low back pain could be harnessed ethically by adding open-label placebo (OLP) treatment to treatment as usual (TAU) for 3 weeks. Pain severity was assessed on three 0- to 10-point Numeric Rating Scales, scoring maximum pain, minimum pain, and usual pain, and a composite, primary outcome, total pain score. Our other primary outcome was back-related dysfunction, assessed on the Roland–Morris Disability Questionnaire. In an exploratory follow-up, participants on TAU received placebo pills for 3 additional weeks. We randomized 97 adults reporting persistent low back pain for more than 3 months' duration and diagnosed by a board-certified pain specialist. Eighty-three adults completed the trial. Compared to TAU, OLP elicited greater pain reduction on each of the three 0- to 10-point Numeric Rating Scales and on the 0- to 10-point composite pain scale (<jats:italic toggle="yes">P</jats:italic> < 0.001), with moderate to large effect sizes. Pain reduction on the composite Numeric Rating Scales was 1.5 (95% confidence interval: 1.0-2.0) in the OLP group and 0.2 (−0.3 to 0.8) in the TAU group. Open-label placebo treatment also reduced disability compared to TAU (<jats:italic toggle="yes">P</jats:italic> < 0.001), with a large effect size. Improvement in disability scores was 2.9 (1.7-4.0) in the OLP group and 0.0 (−1.1 to 1.2) in the TAU group. After being switched to OLP, the TAU group showed significant reductions in both pain (1.5, 0.8-2.3) and disability (3.4, 2.2-4.5). Our findings suggest that OLP pills presented in a positive context may be helpful in chronic low back pain. | eng |
| dc.identifier.citation | Carvalho, Cláudia a,* ; Caetano, Joaquim Machado b ; Cunha, Lídia c ; Rebouta, Paula C ; Kaptchuk, Ted Jd ; Kirsch, Irving d. .Tratamento aberto com placebo na dor lombar crônica: um ensaio clínico randomizado controlado. PAIN 157(12):p 2766-2772, dezembro de 2016. | DOI: 10.1097/j.pain.000000000000700 | |
| dc.identifier.doi | 10.1097/j.pain.0000000000000700 | |
| dc.identifier.issn | 0304-3959 | |
| dc.identifier.issn | 1872-6623 | |
| dc.identifier.uri | http://hdl.handle.net/10400.12/14002 | |
| dc.language.iso | por | |
| dc.peerreviewed | yes | |
| dc.publisher | Ovid Technologies (Wolters Kluwer Health) | |
| dc.relation.ispartof | Pain | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.title | Open-label placebo treatment in chronic low back pain: A randomized controlled trial | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 2772 | |
| oaire.citation.issue | 12 | |
| oaire.citation.startPage | 2766 | |
| oaire.citation.title | Pain | |
| oaire.citation.volume | 157 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 |